2025年7月9日，由中国木材与木制品流通协会主办，中国建博会（广州）为合作平台，广东领尚科技实业有限公司、广东欧派克家居智能科技有限公司、 佛山市极威新材料有限公司共同支持的"中国品牌，链动全球——2025家居行业强国品牌论坛"在广州成功召开。 中国木材与木制品流通协会会长李佳峰，副会长兼木门窗专业委员会执行会长张鹏，中国对外贸易广州展览有限公司副总经理李德为，各省市地方协会秘 书长，以及来自全国门窗、定制、人造板、家具，五金、涂料、设备等上下游产业链代表出席会议。会议由中国木材与木制品流通协会副秘书长黄楠主 持。 李德为副总经理代表中国对外贸易广州展览有限公司，对大家的到来表示热烈欢迎！他表示，中国木材与木制品流通协会是中国建博会（广州）的老朋 友，连续五年邀请行业头部企业齐聚展会，共同探讨大家居建装行业高质量发展之路。本届中国建博会（广州）通过"两个重塑、两个革新"为家居业界搭 建共荣、共聚、共生的大舞台，与全行业同仁携手构建商业转化+趋势引领+生态共建的价值共同体，让每一次展会成为企业穿越周期的桥梁。 主题演讲环节，北京闼闼门业有限公司副总裁张岩作了《以品牌思维破内卷市场》发言，张总坦言，产能过剩是行 ...

7月的广州，热浪与商流一道升温，第27届中国建博会（广州）火热开场。今年这场生态大展中，家居新范式观察到一个新现象——"饰面板"这一常被视 作"基材外衣"或者"设计附属"的品类，正因消费习惯转变、产业调整等因素，进一步从"幕后"走向"台前"。 板材开枝散叶，饰面板成"主角" 大行业来看，中国是人造板生产、消费和贸易第一大国，人造板产量已经连续多年增长。据《中国绿色时报》2025年6月26日报道，我国人造板总生产能 力约为3.66亿立方米，产品产值达到7640亿元。但行业的产品结构在深度调整，一些原来做刨花板、复合板等基材的企业，纷纷加大了饰面板的产研力 度，以提高产品附加值。 以板材行业代表性上市公司华立股份为例，其2024年年报显示，公司饰面板业务实现收入3.10亿元，同比大幅增长66.71%，增速是同期复合板业务的六倍 还多。今年6月5日 ，华立股份又竣工投产了安徽华富立生产基地一期，预计月产能达8万张饰面板。 更值得注意的是，其饰面板业务的毛利率升至18.74%，较上年上涨5.37个百分点，成为拉动企业利润增长的关键板块。 家居新范式在本次广州建博会的展商交流中发现，定制家居融合发展是饰面板"进化"的重 ...

Core Viewpoint - West Fraser Timber Co. Ltd. is set to hold an analysts' conference call to discuss its second quarter 2025 financial and operating results on July 24, 2025 [1][2]. Group 1: Conference Call Details - The conference call will be chaired by Mr. Sean McLaren, President and Chief Executive Officer of West Fraser [2]. - Participants can join the call by dialing a toll-free number or through a webcast [1][2]. - The financial and operating results will be released on July 23, 2025, one day prior to the call [2]. Group 2: Company Overview - West Fraser is a diversified wood products company with over 50 facilities across Canada, the United States, the United Kingdom, and Europe [3]. - The company promotes sustainable forest practices and produces a variety of products including lumber, engineered wood products, pulp, and newsprint [3]. - West Fraser's products are utilized in home construction, repair and remodeling, as well as in industrial applications and paper products [3].

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, ...

Group 1 - West Fraser Timber Co. Ltd. has renewed its $1 billion credit facility and extended its maturity from July 2028 to May 2030 [1] - The company has increased its existing term loan from $200 million to $300 million, maturing in May 2028 [1] - The renewed credit facility is undrawn and available on similar terms as the previous facility [1] Group 2 - As of the end of Q1 2025, West Fraser had over $1.4 billion in available liquidity, enhancing its near-term financial flexibility [2] - The renewal and expansion of the credit facilities further strengthen the company's liquidity position [2] Group 3 - West Fraser is a diversified wood products company with over 50 facilities across Canada, the United States, the United Kingdom, and Europe [3] - The company produces a variety of products including lumber, engineered wood products, pulp, and newsprint, which are used in various applications such as home construction and industrial uses [3]

Core Viewpoint - West Fraser Timber Co. Ltd. has released its 2024 Sustainability Report, highlighting its commitment to sustainability alongside solid financial performance, and detailing progress made towards environmental, social, and governance goals [1][2]. Sustainability Achievements - The report outlines key achievements for 2024, including a 22% reduction in scope 1 and 2 emissions compared to 2019 levels, and a 13% reduction in scope 3 emissions compared to 2020 levels, both on track to meet 2030 GHG reduction targets [5]. - Manufacturing operations were powered by 75% renewable energy, with all mills progressing on energy reduction road maps [5]. - The company invested $4.3 million through 800 partnerships, focusing on youth support and mental health improvements in rural areas [5]. Partnerships and Community Engagement - West Fraser signed an agreement with the Lake Babine Nation's forestry company to secure long-term fibre supply, recognizing the Nation's role as a resource steward, pending approval from the Government of British Columbia [5]. - The company promotes sustainable forest practices and responsible sourcing through its Sustainable Forest and Wood Procurement Policy, implemented in 2024 [5]. Company Overview - West Fraser is a diversified wood products company with over 50 facilities across Canada, the United States, the United Kingdom, and Europe, producing a range of products including lumber, engineered wood products, and pulp [3].

Atea Pharmaceuticals (AVIR) Update / Briefing May 14, 2025 10:00 AM ET Speaker0 Good morning, and welcome to the ATEA Pharmaceuticals Virtual KOL event. At this time, all attendees are in a listen only mode. A question and answer session will follow the formal presentations and fireside chat. As a reminder, this call is being recorded, a replay will be made available on the ATIA website following the conclusion of the event. I'd now like to turn the call over to Doctor. J. P. Somodosi, Founder, Chairman and ...

Core Insights - Atea Pharmaceuticals is advancing its Phase 3 clinical trials for the combination regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), with ongoing patient enrollment in the C-BEYOND trial in the US and Canada, and plans to initiate the C-FORWARD trial globally [4][11][12] - The company reported promising Phase 2 results, indicating a high sustained virologic response (SVR12) rate of 98% among treatment-adherent patients and 95% overall, showcasing the regimen's potential as a best-in-class treatment for HCV [7][11] - Atea's financial results for Q1 2025 show a decrease in research and development expenses to $29.6 million, down from $57.6 million in Q1 2024, attributed to the completion of a previous COVID-19 trial and a focus on HCV development [16][20] Company Updates - Atea is hosting a virtual key opinion leader (KOL) investor event on May 14, 2025, to discuss HCV treatment challenges and the potential of its drug regimen, replacing the traditional earnings call for Q1 2025 [5][6] - The company has engaged Evercore to explore strategic alternatives to enhance shareholder value, including potential partnerships or acquisitions, while also reducing its workforce by approximately 25% to save around $15 million through 2027 [14][15] Financial Performance - As of March 31, 2025, Atea reported cash, cash equivalents, and marketable securities totaling $425.4 million, a decrease from $454.7 million at the end of 2024 [15][22] - The net loss for Q1 2025 was $34.3 million, compared to a net loss of $63.2 million in Q1 2024, reflecting improved operational efficiency [20][22] Clinical Development - The Phase 3 program includes two trials, C-BEYOND and C-FORWARD, each aiming to enroll approximately 880 treatment-naïve patients, comparing the BEM/RZR regimen to the standard sofosbuvir and velpatasvir regimen [11][12] - The primary endpoint for both trials is achieving HCV RNA levels below the lower limit of quantitation at 24 weeks, ensuring consistent evaluation across patient groups [12][13]

Louisiana-Pacific Corporation's (LPX) , or LP, reported better-than-expected first-quarter 2025 results, with adjusted earnings and net sales beating the Zacks Consensus Estimate. On a year-over-year basis, the bottom line declined while the top line remained flat. The quarter's performance reflects strength in the company's Siding business, mainly backed by ExpertFinish growth, share gains in new residential construction and improving shed market. This growth was partially offset by soft contributions from ...

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When Co-Administered with Standard HIV Treatment Regimen Bemnifosbuvir Was Generally Safe and Well Tolerated with No Dose Adjustment Needed in Phase 1 Studies in Participants with Hepatic or Renal Impairment Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, ...